Partnerships Built on Complementary Strengths

The OSUCCC – James Drug Development Institute (DDI) partners with pharmaceutical, biotech and venture capital companies to bridge the gap between drug discovery and early clinical development, accelerating development timelines and delivering innovative treatments to patients sooner. 

The DDI:

  • Provides prospective pharmaceutical and biotech partners with a portfolio of innovative compounds and technologies
  • Leverages a network of subject-matter experts to maximize commercial value
  • Offers flexible agreement models such as licensing, co-development, new business ventures and research support

Partnering with the DDI provides earlier access to new innovative drug candidates with reduced development time and costs, increasing the value of your portfolio.

DDI Partnering Models Tailored to Company Needs

  • Provides access to a broad portfolio of early-stage, innovative compounds and technologies
  • Incorporates an “Alliance Management” team structure for the duration of the partnership
  • Collaboratively builds development plans and strategies, with timelines, milestones, resources and budgets
  • Offers flexible agreement models, including:
    • Sponsored Research
      Pharma supports Ohio State research projects, drawing on the expertise of established clinicians and scientists
    • Co-Development
      The DDI and Pharma enter a co-development partnership to advance a drug candidate, sharing resources and risk
    • Licensing
      An Ohio State-developed therapeutic/technology is directly out-licensed to Pharma at any stage of development
    • Spin-Out Ventures
      The DDI and Pharma establish a new business venture to develop a drug candidate

To learn more, read about our portfoliosuccess stories and team. Or email us at

Contact the DDI

Phone: 614-685-6957 

Meet Us

The DDI Team will be at the following conference.

AACR Annual Meeting

Atlanta, Ga.
March 30-April 3, 2019

Schedule a Meeting

Support the DDI

Donate Now